Valuation: Senzime AB

Market Cap 58Cr 6.1Cr 5.3Cr 4.93Cr 4.53Cr 8.56Cr 582.21Cr 8.69Cr 23Cr 289.85Cr 23Cr 22Cr 971.92Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 58Cr 6.1Cr 5.3Cr 4.93Cr 4.53Cr 8.56Cr 582.21Cr 8.69Cr 23Cr 289.85Cr 23Cr 22Cr 971.92Cr EV / Sales 2026 *
4.56x
EV / Sales 2027 * 2.85x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 week+2.78%
1 month-14.55%
3 months-21.86%
6 months-26.00%
Current year-31.48%
1 week 3.59
Extreme 3.59
3.8
1 month 3.54
Extreme 3.545
4.4
Current year 3.54
Extreme 3.545
6
1 year 3.54
Extreme 3.545
7.22
3 years 3.54
Extreme 3.545
9.6
5 years 2.6
Extreme 2.605
24.8
10 years 2.6
Extreme 2.605
28.5
Manager TitleAgeSince
Chief Executive Officer 53 03/05/2023
Director of Finance/CFO 56 01/01/2022
Chief Tech/Sci/R&D Officer 50 01/01/2023
Director TitleAgeSince
Chairman 53 03/05/2023
Director/Board Member 70 01/01/2016
Director/Board Member 63 05/03/2020
Date Insider Type Main position Quantity % Market Cap.
09/12/25 Buy

Director

15,000 0.0095%
09/12/25 Sell

Director

15,000 0.0095%
28/11/25 Buy

Director

15,900 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+2.78%-49.11%-22.51% 6.1Cr
+0.09%+2.56%-16.24%-5.06% 18TCr
-0.37%+2.62%-5.37%-2.70% 11TCr
-0.29%+0.47%+8.83%+66.58% 6.06TCr
+3.50%+0.47%+28.65%+49.27% 5.18TCr
+0.10%+5.92%-7.09%-40.56% 4.56TCr
+0.41%+1.37% - - 3.32TCr
+11.95%+16.65%+3.32%-33.00% 3.15TCr
+0.40%+3.89%+42.51%-7.36% 2.4TCr
-1.22%+6.69%+0.84%+1.26% 2.23TCr
Average +1.46%+4.65%+0.70%+0.66% 5.61TCr
Weighted average by Cap. +0.92%+3.49%-1.37%+4.40%

Financials

2026 *2027 *
Net sales 13Cr 1.34Cr 1.16Cr 1.08Cr 99.47L 1.88Cr 127.81Cr 1.91Cr 5.01Cr 64Cr 5.03Cr 4.92Cr 213.37Cr 20Cr 2.14Cr 1.86Cr 1.73Cr 1.59Cr 3Cr 204.18Cr 3.05Cr 8.01Cr 101.65Cr 8.03Cr 7.86Cr 340.85Cr
Net income -6.89Cr -72.24L -62.8L -58.45L -53.67L -1.01Cr -69Cr -1.03Cr -2.7Cr -34Cr -2.71Cr -2.65Cr -115.12Cr -3.68Cr -38.58L -33.54L -31.22L -28.66L -54.13L -37Cr -54.97L -1.44Cr -18Cr -1.45Cr -1.42Cr -61Cr
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
31/26/31 SEK 3.700 -.--% 1,19,337
30/26/30 SEK 3.700 +1.23% 39,070
29/26/29 SEK 3.655 -.--% 88,545
28/26/28 SEK 3.655 -0.68% 58,445
27/26/27 SEK 3.680 +2.22% 1,36,471

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SEZI Stock